Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

(RTTNews) - Protara Therapeutics, Inc. (TARA), a clinical-stage company, is scheduled to host a conference call and live webcast to review new interim data from its phase 2 ADVANCED-2 trial on ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...

Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel effort in bladder cancer during a fireside chat at TD Cowen’s 46th Annual ...

The company reported strong efficacy and a clean safety profile from its ongoing Phase 2 Advanced-2 bladder cancer trial. ・Durability signals were notable, with 68% of BCG-unresponsive patients and 66 ...

Data from the IMvigor011 phase 3 study shows that adjuvant atezolizumab (Tecentriq) significantly boosts the reduction and clearance of circulating tumor DNA (ctDNA). Presented at ...